4th Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Healthcare transparency, costs and access to affordable medication and other healthcare items and services.

LobbyistCovered position, as disclosed
DEAN ROSEN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. S. 1895, No Surprises Act. S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act

LobbyistCovered position, as disclosed
LAUREN ARONSON —
DEAN ROSEN —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: S. 1895 (116th), H.R. 3 (116th), S. 2543 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.